Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | CRHBP | P24387 | 2/20 | 0.66 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856718 | 0.87 | MAPT (0.61) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| Ammonia Solution, Strong SCHEMBL28615378 | 0.84 | KMT2A (0.70) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL3405363 | 0.84 | CRHBP (0.61) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL913213 | 0.83 | KMT2A (0.63) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL5788649 | 0.82 | KMT2A (0.72) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL3410886 | 0.82 | CRHBP (0.64) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL856815 | 0.82 | MAPT (0.70) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL29762330 | 0.82 | MAPT (0.70) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL9884923 | 0.81 | HRH4 (0.64) | KMT2ANPSR1HRH4PKMKDM4E | |
| SCHEMBL13326955 | 0.81 | KMT2A (1.00) | KMT2ACRHBPCRHR2NPSR1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4180436-A1 | TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | Neusco Biotech Limited (CN) | 2023-05-17 | — | — | EP | disclosed |
| EP-3458067-B1 | TREATMENT OF NEUROLOGICAL DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2020-12-30 | — | — | EP | disclosed |
| EP-3565810-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2019-11-13 | — | — | EP | disclosed |
| WO-2019101853-A1 | TREATMENT OF SKIN DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2019-05-31 | — | — | WO | disclosed |
| WO-2018127801-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-07-12 | — | — | WO | disclosed |
| WO-2017198346-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017198347-A1 | TREATMENT OF SKIN LESIONS | PIQUR THERAPEUTICS AG (CH) | 2017-11-23 | — | — | WO | disclosed |
| EP-2250998-B1 | SKIN WHITENING AGENT AND EXTERNAL PREPARATION FOR THE SKIN | SHISEIDO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8962834-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8563552-B2 | Whitening agent and skin external preparation | SHISEIDO COMPANY LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-7589197-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY (TW) | 2009-09-15 | — | — | US | disclosed |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2009103652-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
| EP-2003131-A1 | AMINOPYRROLIDINE COMPOUND | Taisho Pharmaceutical Co. Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-6342503-B1 | ANTIDEPRESSANTS, EATING DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2002-01-29 | — | — | US | disclosed |
| US-6107301-A | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| CN-1142817-A | 1N-alkyl-N-arylpyrimidinamines and derivatives thereof | DU PONT MERCK PHARMA (US) | 1997-02-12 | — | — | CN | disclosed |
| EP-0723533-A1 | 1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010506-A1 | 1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TYMS, TYMP, HPRT1 | KMT2A 2400/4885CRHBP 4465/4885CRHR2 4573/4885 |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, APOB | KMT2A 2755/4885CRHBP 1631/4885CRHR2 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.